Instrument Inactif

Autres langues Entasis Therapeutics Holdings Inc.

Actions

ETTX

US2936141033

Recherche biotechnologique et médicale

Autres langues

19/10/22	Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022
13/07/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index
11/07/22	Innoviva Acquires Remaining Stake in Entasis Therapeutics
11/07/22	Entasis Therapeutics : Termination of a Material Definitive Agreement - Form 8-K
11/07/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
11/07/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index
11/07/22	Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.
24/06/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index
24/06/22	Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index
10/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
09/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
23/05/22	Entasis Therapeutics : Innoviva to Acquire Entasis Therapeutics - Form 8-K
23/05/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
23/05/22	ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX
23/05/22	Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell
23/05/22	Innoviva to Acquire Entasis Therapeutics
23/05/22	Innoviva to Acquire Entasis Therapeutics
18/05/22	Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
17/05/22	Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference
17/05/22	Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
28/04/22	Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
27/04/22	ENTASIS THERAPEUTICS HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
27/04/22	Entasis Therapeutics : Announces First Quarter 2022 Financial Results and Provides Business Update - Form 8-K
27/04/22	Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
27/04/22	Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update